- PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
-
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
- -
-
Page/Page column 44-45
(2016/10/11)
-
- Novel Compounds
-
The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
- -
-
Page/Page column 68
(2012/04/18)
-
- 4-AMINO-PYRIMIDINE DERIVATIVES
-
4-Amino-pyrimidine derivatives of Formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.
- -
-
Page/Page column 76
(2009/07/25)
-
- First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
-
SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the
- Provins, Laurent,Christophe, Bernard,Danhaive, Pierre,Dulieu, Jacques,Durieu, Véronique,Gillard, Michel,Lebon, Florence,Lengelé, Sébastien,Quéré, Luc,Van Keulen, Berendjan
-
p. 1834 - 1839
(2007/10/03)
-
- CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
-
The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
- -
-
Page/Page column 32-33
(2008/06/13)
-